Business
Speech recognition for clinical trials
Speech recognition for clinical trials.
About this update from Cambridge Cognition Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 3178H Cambridge Cognition Holdings PLC 07 June 2017 \n\nCambridge Cognition Holdings Plc\n('Cambridge Cognition' or the 'Company')\nSpeech recognition for clinical trials\n \nCambridge Cognition Holdings PLC (Cambridge, UK - LSE: COG, 'Company'), the neuroscience digital health company, is pleased to announce its application of automatic speech recognition (\"ASR\") technology to develop new products to enable scalable, language-based clinical assessment to reduce clinical trial variability and costs and increase overall clinical trial efficiency.\nThe Company is now employing commercially available Artificial Intelligence (\"AI\") and ASR technologies to make language-based verbal cognitive assessments that are scalable, automated and consistent, which in turn will reduce human error between trial centres and between trial subjects. The first products are expected to be available commercially in mid 2018.\nLanguage is a unique human capability that exhibits measurable changes in many psychiatric and neurological conditions including Alzheimer's disease, depression and schizophrenia. To date it has been difficult for clinical researchers to perform language-based assessments or measure verbal cognitive changes without highly trained experts. Now this new combination of speech recognition technology with Cambridge Cognition's validated computerised tests will make this possible.\nThis new platform, powered by AI, will allow innovative types of language-based cognitive assessment raising the possibility of delivering clinician-administered cognitive testing remotely and directly into people's homes for health assessments and trial subject profiling and triaging. The company also sees future opportunities to provide a means of monitoring well-established clinical interactions objectively for quality control, which will reduce reliance on human raters. This could have a significant impact on trial cost and speed of recruitment.\nThe Company's ASR-based technology will be unveiled formally at the Alzheimer's Association Technology and Dementia preconference in London on July 15 2017, where data from a proof of concept study will be presented.\nJenny Barnett, PhD, Chief Scientific Officer, Cambridge Cognition said: \"We see significant opportunities to improve upon rater-administered tests such as the MMSE...